Gilead Sciences, Inc. (NASDAQ:GILD) Shares Sold by Mn Services Vermogensbeheer B.V.

Mn Services Vermogensbeheer B.V. lessened its holdings in Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 3.1% during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 591,655 shares of the biopharmaceutical company's stock after selling 18,900 shares during the quarter. Mn Services Vermogensbeheer B.V.'s holdings in Gilead Sciences were worth $47,930,000 at the end of the most recent reporting period.

Other institutional investors also recently bought and sold shares of the company. PCA Investment Advisory Services Inc. purchased a new stake in shares of Gilead Sciences in the second quarter worth about $25,000. Tompkins Financial Corp boosted its position in Gilead Sciences by 223.1% in the 3rd quarter. Tompkins Financial Corp now owns 349 shares of the biopharmaceutical company's stock worth $26,000 after purchasing an additional 241 shares in the last quarter. OFI Invest Asset Management acquired a new stake in shares of Gilead Sciences during the 3rd quarter worth approximately $26,000. Fortitude Family Office LLC purchased a new position in shares of Gilead Sciences during the 4th quarter valued at approximately $29,000. Finally, Sanctuary Wealth Management L.L.C. acquired a new position in shares of Gilead Sciences in the 4th quarter valued at $33,000. 83.67% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling

In other Gilead Sciences news, CFO Andrew D. Dickinson sold 5,000 shares of the business's stock in a transaction dated Tuesday, January 16th. The shares were sold at an average price of $85.78, for a total value of $428,900.00. Following the transaction, the chief financial officer now directly owns 101,534 shares in the company, valued at approximately $8,709,586.52. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. In other Gilead Sciences news, CFO Andrew D. Dickinson sold 5,000 shares of the firm's stock in a transaction on Tuesday, January 16th. The stock was sold at an average price of $85.78, for a total transaction of $428,900.00. Following the completion of the sale, the chief financial officer now owns 101,534 shares of the company's stock, valued at $8,709,586.52. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, insider Merdad Parsey sold 2,000 shares of the company's stock in a transaction on Wednesday, February 28th. The shares were sold at an average price of $73.18, for a total value of $146,360.00. Following the completion of the transaction, the insider now directly owns 100,936 shares in the company, valued at approximately $7,386,496.48. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 9,000 shares of company stock worth $721,180. Insiders own 0.16% of the company's stock.

Analysts Set New Price Targets

A number of research analysts have weighed in on the stock. Oppenheimer cut their price objective on shares of Gilead Sciences from $115.00 to $105.00 and set an "outperform" rating for the company in a report on Monday, February 12th. Mizuho lowered their price target on Gilead Sciences from $101.00 to $90.00 and set a "buy" rating on the stock in a research report on Thursday, February 22nd. Truist Financial lowered Gilead Sciences from a "buy" rating to a "hold" rating and dropped their price objective for the company from $91.00 to $82.00 in a report on Thursday, February 22nd. Wells Fargo & Company reduced their target price on Gilead Sciences from $84.00 to $77.00 and set an "equal weight" rating for the company in a research note on Monday, March 4th. Finally, StockNews.com raised shares of Gilead Sciences from a "buy" rating to a "strong-buy" rating in a research note on Tuesday, March 26th. One research analyst has rated the stock with a sell rating, nine have issued a hold rating, five have assigned a buy rating and one has issued a strong buy rating to the company's stock. According to data from MarketBeat.com, the stock presently has an average rating of "Hold" and a consensus target price of $85.36.

Gilead Sciences Price Performance

GILD stock traded down $0.58 during mid-day trading on Friday, reaching $68.07. The company's stock had a trading volume of 5,691,760 shares, compared to its average volume of 6,553,057. The company has a current ratio of 1.43, a quick ratio of 1.27 and a debt-to-equity ratio of 1.08. The company's 50 day moving average is $72.79 and its two-hundred day moving average is $76.82. Gilead Sciences, Inc. has a fifty-two week low of $67.62 and a fifty-two week high of $87.86. The stock has a market cap of $84.75 billion, a PE ratio of 15.13, a P/E/G ratio of 0.87 and a beta of 0.19.

Gilead Sciences (NASDAQ:GILD - Get Free Report) last posted its quarterly earnings results on Tuesday, February 6th. The biopharmaceutical company reported $1.72 EPS for the quarter, missing the consensus estimate of $1.76 by ($0.04). The company had revenue of $7.12 billion during the quarter, compared to analyst estimates of $7.10 billion. Gilead Sciences had a net margin of 20.89% and a return on equity of 38.85%. Gilead Sciences's revenue for the quarter was down 3.7% compared to the same quarter last year. During the same period in the prior year, the business posted $1.67 EPS. Equities research analysts expect that Gilead Sciences, Inc. will post 7.08 EPS for the current year.

Gilead Sciences Increases Dividend

The company also recently disclosed a quarterly dividend, which was paid on Thursday, March 28th. Investors of record on Friday, March 15th were issued a $0.77 dividend. The ex-dividend date of this dividend was Thursday, March 14th. This represents a $3.08 dividend on an annualized basis and a dividend yield of 4.52%. This is a positive change from Gilead Sciences's previous quarterly dividend of $0.75. Gilead Sciences's dividend payout ratio is currently 68.44%.

Gilead Sciences Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.